At the time of writing, Alnylam Pharmaceuticals Inc [ALNY] stock is trading at $293.69, down -0.40%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ALNY shares have lost -1.03% over the last week, with a monthly amount glided 7.69%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, Goldman upgraded its rating to Buy on August 16, 2024, and elevated its price target to $370. On February 16, 2024, downgrade downgraded it’s rating to Neutral but maintained its price target of $173 on the stock. Wolfe Research started tracking the stock assigning a Peer Perform rating. Wells Fargo initiated its recommendation with a Equal Weight and recommended $171 as its price target on December 08, 2023. In a note dated October 11, 2023, Oppenheimer downgraded an Perform rating on this stock.
For the past year, the stock price of Alnylam Pharmaceuticals Inc fluctuated between $141.98 and $304.39. Currently, Wall Street analysts expect the stock to reach $254.21 within the next 12 months. Alnylam Pharmaceuticals Inc [NASDAQ: ALNY] shares were valued at $293.69 at the most recent close of the market. An investor can expect a potential drop of -13.44% based on the average ALNY price forecast.
Analyzing the ALNY fundamentals
According to Alnylam Pharmaceuticals Inc [NASDAQ:ALNY], the company’s sales were 2.34B for trailing twelve months, which represents an 107.00% jump. Gross Profit Margin for this corporation currently stands at 0.87% with Operating Profit Margin at 0.04%, Pretax Profit Margin comes in at -0.03%, and Net Profit Margin reading is -0.03%. To continue investigating profitability, this company’s Return on Assets is posted at -0.02, Equity is 0.48 and Total Capital is 0.03. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -804.98.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 291.08 points at the first support level, and at 288.47 for the second support level. However, for the 1st resistance point, the stock is sitting at 298.67, and for the 2nd resistance point, it is at 303.66.
Ratios To Look Out For
It is important to note that Alnylam Pharmaceuticals Inc [NASDAQ:ALNY] has a current ratio of 3.01. As well, the Quick Ratio is 2.93, while the Cash Ratio is 0.92. Considering the valuation of this stock, the price to sales ratio is 16.08.
Transactions by insiders
Recent insider trading involved Greenstreet Yvonne, Chief Executive Officer, that happened on Aug 20 ’24 when 15000.0 shares were sold. Officer, Greenstreet Yvonne completed a deal on Aug 20 ’24 to buy 15000.0 shares. Meanwhile, CSO & EVP, Head of Research Fitzgerald Kevin Joseph sold 22025.0 shares on Aug 12 ’24.
